VENLAFAXINE HYDROCHLORIDE- venlafaxine hydrochloride capsule, extended release

Venlafaxine Hydrochloride by

Drug Labeling and Warnings

Venlafaxine Hydrochloride by is a Prescription medication manufactured, distributed, or labeled by Asclemed USA, Inc., ASCLEMED USA INC. DBA ENOVACHEM. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING: SUICIDAL THOUGHTS AND BEHAVIORS

    Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and emergence ofsuicidal thoughts and behaviors [see Warnings and Precautions (5.1)] . Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients [seeUse in Specific Populations (8.4)].

  • 1 INDICATIONS AND USAGE

    Venlafaxine hydrochloride extended-release capsules are indicated in adults for the treatment of:


  • 2 DOSAGE AND ADMINISTRATION

    2.1 General Administration Information

    Administer venlafaxine hydrochloride extended-release capsules as a single dose with food, either in the morning or in the evening at approximately the same time each day [see Clinical Pharmacology (12.3)] . Swallow capsules whole with fluid. Do not divide, crush, chew, or place in water.

    The capsule may also be administered by carefully opening the capsule and sprinkling the entire contents on a spoonful of applesauce. This drug/food mixture should be swallowed immediately without chewing and followed with a glass of water to ensure complete swallowing of the pellets (spheroids).


    2.2 Major Depressive Disorder

    For most patients, the recommended starting dose for venlafaxine hydrochloride extended-release capsules is 75 mg per day, administered in a single dose. For some patients, it may be desirable to start at 37.5 mg per day for 4 to 7 days to allow new patients to adjust to the medication before increasing to 75 mg per day. Patients not responding to the initial 75 mg per day dose may benefit from dose increases to a maximum of 225 mg per day. Dose increases should be in increments of up to 75 mg per day, as needed, and should be made at intervals of not less than 4 days. In the clinical studies establishing efficacy, upward titration was permitted at intervals of 2 weeks or more.

    2.3 Generalized Anxiety Disorder

    For most patients, the recommended starting dose for venlafaxine hydrochloride extended-release capsules is 75 mg per day, administered in a single dose. For some patients, it may be desirable to start at 37.5 mg per day for 4 to 7 days to allow new patients to adjust to the medication before increasing to 75 mg per day. Patients not responding to the initial 75 mg per day dose may benefit from dose increases to a maximum of 225 mg per day. Dose increases should be in increments of up to 75 mg per day, as needed, and should be made at intervals of not less than 4 days.

    2.4 Social Anxiety Disorder (Social Phobia)

    The recommended dose is 75 mg per day, administered in a single dose. There was no evidence that higher doses confer any additional benefit.

    2.5 Panic Disorder

    The recommended starting dose is 37.5 mg per day of venlafaxine hydrochloride extended-release capsules for 7 days. Patients not responding to 75 mg per day may benefit from dose increases to a maximum of approximately 225 mg per day. Dose increases should be in increments of up to 75 mg per day, as needed, and should be made at intervals of not less than 7 days.

    2.6 Screen for Bipolar Disorder Prior to Starting Venlafaxine Hydrochloride Extended-Release Capsules


    Prior to initiating treatment with venlafaxine hydrochloride extended-release capsules, screen patients for a personal or family history of bipolar disorder, mania, or hypomania [see Warnings and Precautions (5.6)] .

    2.7 Switching Patients from Venlafaxine Hydrochloride Tablets

    Patients with depression who are currently being treated with Effexor may be switched to venlafaxine hydrochloride extended-release capsules at the nearest equivalent dose (mg per day), e.g., 37.5 mg venlafaxine twice a day to 75 mg venlafaxine hydrochloride extended-release capsules once daily. However, individual dosage adjustments may be necessary.

    2.8  Dosage Recommendations for Patients with Hepatic Impairment


    Reduce the venlafaxine hydrochloride extended-release capsules total daily dose by 50% in patients with mild (Child-Pugh Class A) to moderate (Child-Pugh Class B) hepatic impairment. Reduce the total daily dose by 50% or more in patients with severe hepatic impairment (Child-Pugh Class C) or hepatic cirrhosis [seeUse in Specific Populations (8.6)].

    2.9 Dosage Recommendations for Patients with Renal Impairment

    Reduce the venlafaxine hydrochloride extended-release capsules total daily dose by 25% to 50% in patients with mild (CLcr 60 to 89 mL/min) or moderate (CLcr 30 to 59 mL/min) renal impairment. Reduce the total daily dose by 50% or more in patients undergoing hemodialysis or with severe renal impairment (CLcr < 30 mL/min). Because there was much individual variability in clearance between patients with renal impairment, individualization of dosage is recommended in some patients [seeUse in Specific Populations (8.7)].

    2.10 Discontinuing Treatment with Venlafaxine Hydrochloride Extended-Release Capsules

    A gradual reduction in the dose, rather than abrupt cessation, is recommended when discontinuing therapy with venlafaxine hydrochloride extended-release capsules. In clinical studies with venlafaxine hydrochloride extended-release capsules, tapering was achieved by reducing the daily dose by 75 mg at one-week intervals. Individualization of tapering may be necessary. In some patients, discontinuation may need to occur over a period of several months [see Warnings and Precautions (5.7)] .

    2.11 Switching Patients to or from a Monoamine Oxidase Inhibitor (MAOI) Antidepressant

    At least 14 days must elapse between discontinuation of an MAOI antidepressant and initiation of venlafaxine hydrochloride extended-release capsules. In addition, at least 7 days must elapse after stopping venlafaxine hydrochloride extended-release capsules before starting an MAOI antidepressant [see Contraindications (4), Warnings and Precautions (5.2), and Drug Interactions (7.1)] .

  • 3 DOSAGE FORMS AND STRENGTHS

    Venlafaxine hydrochloride extended-release capsules, USP are available in the following strengths:


    • 37.5 mg extended-releasecapsule: white to off white spherical to oval pellets filled in empty hard gelatin capsule shell (size ‘3’) of opaque grey color cap and opaque peach color body imprinted with “E” on cap and “73” on the body with edible black ink.
    • 75 mg extended-releasecapsule:white to off white spherical to oval pellets filled in empty hard gelatin capsule shell (size ‘1’) of opaque peach color cap and opaque peach color body imprinted with “E” on cap and “74” on the body with edible black ink.
    • 150 mg extended-releasecapsule:white to off white spherical to oval pellets filled in empty hard gelatin capsule shell (size ‘0’) of opaque dark orange color cap and opaque dark orange color body imprinted with “E” on cap and “89” on the body with edible black ink.
  • 4 CONTRAINDICATIONS

    Venlafaxine hydrochloride extended-release capsules are contraindicated in patients:


    • with known hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation [see Adverse Reactions (6.2)] .

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Suicidal Thoughts and Behaviors in Adolescents and Young Adults


    In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated patients age 24 years and younger was greater than in placebo-treated patients. There was considerable variation in risk of suicidal thoughts and behaviors among drugs, but there was an increased risk identified in young patients for most drugs studied. There were differences in absolute risk of suicidal thoughts and behaviors across the different indications, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 1.



    Table 1: Risk Differences of the Number of Patients of Suicidal Thoughts and Behaviors in the Pooled Placebo-Controlled Trials of Antidepressants in Pediatric* and Adult Patients



    Age Range
    		Drug-Placebo Difference in Number of Patients of Suicidal Thoughts and Behaviors per 1,000 Patients Treated
    Increases Compared to Placebo
    < 18 years old
    		14 additional patients
    18 to 24 years old
    		5 additional patients

    		Decreases Compared to Placebo
    25 to 64 years old
    		1 fewer patient
    ≥ 65 years old
    		6 fewer patients

    * Venlafaxine hydrochloride extended-release capsules are not approved in pediatric patients.



    It is unknown whether the risk of suicidal thoughts and behaviors in children, adolescents, and young adults extends to longer-term use, i.e., beyond four months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with MDD that antidepressants delay the recurrence of depression and that depression itself is a risk factor for suicidal thoughts and behaviors.


    Monitor all antidepressant-treated patients for any indication for clinical worsening and emergence of suicidal thoughts and behaviors, especially during the initial few months of drug therapy, and at times of dosage changes. Counsel family members or caregivers of patients to monitor for changes in behavior and to alert the healthcare provider. Consider changing the therapeutic regimen, including possibly discontinuing venlafaxine hydrochloride extended-release capsules, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors.

    5.2 Serotonin Syndrome


    Serotonin-norepinephrine reuptake inhibitors (SNRIs), including venlafaxine hydrochloride extended-release capsules, can precipitate serotonin syndrome, apotentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e., MAOIs [see  Contraindications (4), Drug Interactions (7.1)] . Serotonin syndrome can also occur when these drugs are used alone.

    Serotonin syndrome signs and symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures,andgastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). 

    The concomitant use of venlafaxine hydrochloride extended-release capsules with MAOIs is contraindicated. In addition, do not initiate venlafaxine hydrochloride extended-release capsules in a patient being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue byother routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with an MAOI such as linezolid or intravenous methylene blue in a patient taking venlafaxine hydrochloride extended-release capsules, discontinue venlafaxine hydrochloride extended-release capsules before initiating treatment with the MAOI [see Contraindications (4), Drug Interactions (7.1)] .


    Monitor all patients taking venlafaxine hydrochloride extended-release capsules for the emergence of serotonin syndrome. Discontinue treatment with venlafaxine hydrochloride extended-release capsules and any concomitant serotonergic agents immediately if the above symptoms occur, and initiate supportive symptomatic treatment. If concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.

    5.3 Elevated Blood Pressure

    In controlled trials, there were dose-related increases in systolic and diastolic blood pressure, as well as cases of sustained hypertension [seeAdverse Reactions (6.1)].


    Monitor blood pressure before initiating treatment with venlafaxine hydrochloride extended-release capsules and regularly during treatment. Control pre-existing hypertension before initiating treatment with venlafaxine hydrochloride extended-release capsules. Use caution in treating patients with pre-existing hypertension or cardiovascular or cerebrovascular conditions that might be compromised by increases in blood pressure. Sustained blood pressure elevation can lead to adverse outcomes. Cases of elevated blood pressure requiring immediate treatment have been reported with  venlafaxine hydrochloride extended-release capsules. Consider dose reduction or discontinuation of treatment for patients who experience a sustained increase in blood pressure.


    Across all clinical studies with venlafaxine hydrochloride, 1.4% of patients in the venlafaxine hydrochloride extended-release capsules treated groups experienced a ≥15 mm Hg increase in supine diastolic blood pressure (SDBP) ≥105 mm Hg, compared to 0.9% of patients in the placebo groups. Similarly, 1% of patients in the venlafaxine hydrochloride extended-release capsules treated groups experienced a ≥20 mm Hg increase in supine systolic blood pressure (SSBP) with blood pressure ≥180 mm Hg, compared to 0.3% of patients in the placebo groups [see   Adverse Reactions (6.1)].   Treatment with venlafaxine hydrochloride extended-release capsules was associated with sustained hypertension defined as SDBP ≥90 mm Hg and ≥10 mm Hg above baseline for three consecutive on-therapy visits [see   Adverse Reactions (6.1)] . An insufficient number of patients received mean doses of venlafaxine hydrochloride extended-release capsules over 300 mg per day in clinical studies to fully evaluate the incidence of sustained increases in blood pressure at these higher doses.


    5.4 Increased Risk of Bleeding


    Drugs that interfere with serotonin reuptake inhibition, including venlafaxine hydrochloride extended-release capsules, may increase the risk of bleeding events, ranging from ecchymoses, hematomas, epistaxis, petechiae, and gastrointestinal hemorrhage tolife-threatening hemorrhage. Concomitant use of aspirin, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), warfarin, and other anti-coagulants or other drugs known to affect platelet function may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. Based on data from the published observational studies, exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [seeUse in Specific Populations (8.1)].


    Inform patients about the increased risk of bleeding associated with the concomitant use of venlafaxine hydrochloride extended-release capsules and  nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, or other drugs that affect coagulation. Forpatients taking warfarin, carefully monitor coagulation indices when initiating, titrating, or discontinuing venlafaxine hydrochloride extended-release capsules.

    5.5 Angle-Closure Glaucoma

    The pupillary dilation that occurs following use of many antidepressant drugs including venlafaxine hydrochloride extended-release capsules may trigger an angle closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy. Avoid use of antidepressants, including venlafaxine hydrochloride extended-release capsules, in patients with untreated anatomically narrow angles.

    5.6 Activation of Mania or Hypomania

    In patients with bipolar disorder, treating a depressive episode with venlafaxine hydrochloride extended-release capsules or another antidepressant may precipitate a mixed/manic episode. Mania or hypomania was reported in venlafaxine hydrochloride extended-release capsules treated patients in the premarketing studies in MDD, SAD, and PD (see Table 2). Prior to initiating treatment with venlafaxine hydrochloride extended-release capsules, screen for any personal or family history of bipolar disorder, mania, or hypomania.


    Table 2: Incidence (%) of Mania or Hypomania Reported in Venlafaxine Hydrochloride Extended-Release Capsules Treated Patients in the Premarketing Studies
    Indication
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    MDD
    		0.3
    		0
    GAD                                                                      
    		0
    		0.2
    SAD
    		0.2
    		0
    PD
    		0.1
    		0

    5.7 Discontinuation Syndrome

    Discontinuation symptoms have been systematically evaluated in patients taking venlafaxine, including prospective analyses of clinical studies in GAD and retrospective surveys of studies in MDD and SAD. Abrupt discontinuation or dose reduction of venlafaxine at various doses has been found to be associated with the appearance of new symptoms, the frequency of which increased with increased dose level and with longer duration of treatment. Reported symptoms include agitation, anorexia, anxiety, confusion, impaired coordination and balance, diarrhea, dizziness, dry mouth, dysphoric mood, fasciculation, fatigue, flu-like symptoms, headaches, hypomania, insomnia, nausea, nervousness, nightmares, sensory disturbances (including shock-like electrical sensations), somnolence, sweating, tremor, vertigo, and vomiting.


    There have been postmarketing reports of serious discontinuation symptoms which can be protracted and severe. Completed suicide, suicidal thoughts, aggression and violent behavior have been observed in patients during reduction in venlafaxine hydrochloride extended-release capsules dosage, including during discontinuation. Other postmarketing reports describe visual changes (such as blurred vision or trouble focusing) and increased blood pressure after stopping or reducing the dose of venlafaxine hydrochloride extended-release capsules.


    During marketing of venlafaxine hydrochloride extended-release capsules, other SNRIs, and SSRIs, there have been reports of adverse events occurring upon discontinuation of these drugs, particularly when abrupt, including the following: irritability, lethargy, emotional lability, tinnitus, and seizures.

    Patients should be monitored for these symptoms when discontinuing treatment with venlafaxine hydrochloride extended-release capsules. A gradual reduction in the dose, rather than abrupt cessation, is recommended. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the healthcare provider may continue decreasing the dose, but at a more gradual rate. In some patients, discontinuation may need to occur over a period of several months [see Dosage and Administration (2.10)] .

    5.8 Seizures

    Cases of seizure have been reported with venlafaxine therapy. Venlafaxine hydrochloride extended-release capsules has not been systematically evaluated in patients with seizure disorder. Venlafaxine hydrochloride extended-release capsules should be prescribed with caution in patients with a seizure disorder.

    5.9 Hyponatremia

    Hyponatremia can occur as a result of treatment with SNRIs, including venlafaxine hydrochloride extended-release capsules. In many cases, the hyponatremia appears to be the result of the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion. Cases with serum sodium lower than 110 mmol/L have been reported. Elderly patients may be at greater risk of developing hyponatremia with SNRIs. Also, patients taking diuretics, or those who are otherwise volume-depleted, may be at greater risk [see  Use in Specific Populations (8.5)and Clinical Pharmacology (12.3)] . Consider discontinuation of venlafaxine hydrochloride extended-release capsules in patients with symptomatic hyponatremia, and institute appropriate medical intervention.


    Signs and symptoms of hyponatremia include headache, difficulty concentrating, memory impairment, confusion, weakness, and unsteadiness, which may lead to falls. Signs and symptoms associated with more severe and/or acute cases have included hallucination, syncope, seizure, coma, respiratory arrest, and death.

    5.10 Weight and Height Changes in Pediatric Patients

    Weight Changes


    The average change in body weight and incidence of weight loss (percentage of patients who lost 3.5% or more) in the placebo-controlled pediatric studies in MDD, GAD, and SAD are shown in Tables 3 and 4.

    Table 3: Average Change in Body Weight (kg) From Beginning of Treatment in Pediatric Patients ain Double-blind, Placebo-controlled Studies of Venlafaxine Hydrochloride Extended-Release Capsules
    Indication
    (Duration)
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    MDD and GAD  
    (4 pooled studies, 8 weeks)
    		-0.45 (n = 333)
    		+0.77 (n = 333)
    SAD (16 weeks)
    		-0.75 (n = 137)
    		+0.76 (n = 148)

    aVenlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.

    Table 4: Incidence (%) of Pediatric Patients aExperiencing Weight Loss (3.5% or more) in Double-blind, Placebo-controlled Studies of Venlafaxine Hydrochloride Extended-Release Capsules
    aVenlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.
    bp < 0.001 versus placebo
    Indication
    (Duration)
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    MDD and GAD  
    (4 pooled studies, 8 weeks)
    		18 b(n = 333)
    		3.6 (n = 333)
    SAD (16 weeks)
    		47 b(n = 137)
    		14 (n = 148)

    Weight loss was not limited to patients with anorexia [see Warnings and Precautions (5.11)] .


    The risks associated with longer term venlafaxine hydrochloride extended-release capsules use were assessed in an open-label MDD study of children and adolescents who received venlafaxine hydrochloride extended-release capsules for up to six months. The children and adolescents in the study had increases in weight that were less than expected, based on data from age- and sex-matched peers. The difference between observed weight gain and expected weight gain was larger for children (<12 years old) than for adolescents (≥12 years old).

    Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients [ Use in Specific Populations (8.4)] .


    Height Changes


    Table 5 shows the average height increase in pediatric patients in the short-term, placebo-controlled MDD, GAD, and SAD studies. The differences in height increases in GAD and MDD studies were most notable in patients younger than 12 years old.

    Table 5: Average Height Increases (cm) in Pediatric Patients ain Placebo-controlled Studies of Venlafaxine Hydrochloride Extended-Release Capsules
    a Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.
    bp = 0.041
    Indication
    (Duration)
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    MDD (8 weeks)
    		0.8 (n = 146)
    		0.7 (n = 147)
    GAD (8 weeks)
    		0.3 b(n = 122)
    		1 (n = 132)
    SAD (16 weeks)
    		1 (n = 109)
    		1 (n = 112)

    In the six-month, open-label MDD study, children and adolescents had height increases that were less than expected, based on data from age- and sex-matched peers. The difference between observed and expected growth rates was larger for children (<12 years old) than for adolescents (≥12 years old) [see Use in Specific Populations (8.4)] .

    5.11 Appetite Changes in Pediatric Patients

    Decreased appetite (reported as anorexia) was more commonly observed in venlafaxine hydrochloride extended-release capsules treated patients versus placebo-treated patients in the premarketing evaluation of venlafaxine hydrochloride extended-release capsules for MDD, GAD, and SAD (see Table 6). �


    Venlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients [see Use in Specific Populations (8.4)] .

    Table 6: Incidence (%) of Decreased Appetite and Associated Discontinuation Rates a(%) in Pediatric Patients bin Placebo-controlled Studies of Venlafaxine Hydrochloride Extended-Release Capsules
    aThe discontinuation rates for weight loss were 0.7% for patients receiving either venlafaxine hydrochloride extended-release capsules or placebo.
    bVenlafaxine hydrochloride extended-release capsules are not approved for use in pediatric patients.
    Indication
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    (Duration)
    		Incidence
    		Discontinuation
    		Incidence
    		Discontinuation
    MDD and GAD
        (pooled, 8 weeks)
    		10
    		0
    		3
    		-
    SAD
       (16 weeks)
    		22
    		0.7
    		3
    		0

    5.12 Interstitial Lung Disease and Eosinophilic Pneumonia

    Interstitial lung disease and eosinophilic pneumonia associated with venlafaxine therapy have been rarely reported. The possibility of these events should be considered in venlafaxine hydrochloride extended-release capsules-treated patients who present with progressive dyspnea, cough or chest discomfort. Such patients should undergo a prompt medical evaluation, and discontinuation of venlafaxine hydrochloride extended-release capsules should be considered.

    5.13 Sexual Dysfunction

    Use of SNRIs, including venlafaxine hydrochloride extended-release capsules, may cause symptoms of sexual dysfunction [see Adverse Reactions (6.1)] . In male patients, SNRI use may result in ejaculatory delay or failure, decreased libido, and erectile dysfunction. In female patients, SNRI use may result in decreased libido and delayed or absent orgasm. It is important for prescribers to inquire about sexual function prior to initiation of venlafaxine hydrochloride extended-release capsules and to inquire specifically about changes in sexual function during treatment, because sexual function may not be spontaneously reported. When evaluating changes in sexual function, obtaining a detailed history (including timing of symptom onset) is important because sexual symptoms may have other causes, including the underlying psychiatric disorder. Discuss potential management strategies to support patients in making informed decisions about treatment.

  • 6 ADVERSE REACTIONS


    The following adverse reactions are discussed in more detail in other sections of the labeling:

    6.1 Clinical Studies Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.


    Most Common Adverse Reactions


    The most commonly observed adverse reactions in the clinical study database in venlafaxine hydrochloride extended-release capsules treated patients in MDD, GAD, SAD, and PD (incidence ≥5% and at least twice the rate of placebo) were: nausea (30%), somnolence (15.3%), dry mouth (14.8%), sweating (11.4%), abnormal ejaculation (9.9%), anorexia (9.8%), constipation (9.3%), impotence (5.3%), and decreased libido (5.1%).


    Adverse Reactions Reported as Reasons for Discontinuation of Treatment

    Combined across short-term, placebo-controlled premarketing studies for all indications, 12% of the 3,558 patients who received venlafaxine hydrochloride extended-release capsules (37.5 to 225 mg) discontinued treatment due to an adverse experience, compared with 4% of the 2,197 placebo-treated patients in those studies.


    The most common adverse reactions leading to discontinuation in ≥1% of the venlafaxine hydrochloride extended-release capsules treated patients in the short-term studies (up to 12 weeks) across indications are shown in Table 7.

    Table 7: Incidence (%) of Patients Reporting Adverse Reactions Leading to Discontinuation in Placebo-controlled Clinical Studies (up to 12 Weeks Duration)
    Body System
    Adverse Reaction
    		Venlafaxine Hydrochloride Extended-Release Capsules
    n = 3,558
    		Placebo
    n = 2,197
    Body as a whole
       Asthenia
    		1.7
    		0.5
       Headache
    		1.5
    		0.8
    Digestive system
       Nausea
    		4.3
    		0.4
    Nervous system
       Dizziness
    		2.2
    		0.8
       Insomnia
    		2.1
    		0.6
       Somnolence
    		1.7
    		0.3
    Skin and appendages
    		1.5
    		0.6
       Sweating
    		1
    		0.2

    Common Adverse Reactions in Placebo-controlled Studies

    The number of patients receiving multiple doses of venlafaxine hydrochloride extended-release capsules during the premarketing assessment for each approved indication is shown in Table 8. The conditions and duration of exposure to venlafaxine in all development programs varied greatly, and included (in overlapping categories) open and double-blind studies, uncontrolled and controlled studies, inpatient (venlafaxine hydrochloride only) and outpatient studies, fixed-dose, and titration studies.

     Table 8: Patients Receiving Venlafaxine Hydrochloride Extended-Release Capsules in Premarketing Clinical Studies
    aIn addition, in the premarketing assessment of venlafaxine hydrochloride, multiple doses were administered to 2,897 patients in studies for MDD.
    Indication
    		Venlafaxine Hydrochloride Extended-Release Capsules
    MDD
    		705 a
    GAD
    		1,381
    SAD
    		819
    PD
    		1,314

    The incidences of common adverse reactions (those that occurred in ≥2% of venlafaxine hydrochloride extended-release capsules treated patients [357 MDD patients, 1,381 GAD patients, 819 SAD patients, and 1,001 PD patients] and more frequently than placebo) in venlafaxine hydrochloride extended-release capsules treated patients in short-term, placebo-controlled, fixed- and flexible-dose clinical studies (doses 37.5 to 225 mg per day) are shown in Table 9.


    The adverse reaction profile did not differ substantially between the different patient populations.

    Table 9: Common Adverse Reactions: Percentage of Patients Reporting Adverse Reactions (≥2% and > placebo) in Placebo-controlled Studies (up to 12 Weeks Duration) across All Indications
    aPercentages based on the number of men (venlafaxine hydrochloride extended-release capsules, n = 1,440; placebo, n = 923)
    bPercentages based on the number of women (venlafaxine hydrochloride extended-release capsules, n = 2,118; placebo, n = 1,274)
    Body System
    Adverse Reaction
    		Venlafaxine Hydrochloride Extended-Release Capsules
    n = 3,558
    		Placebo
    n = 2,197
    Body as a whole
       Asthenia
    		12.6
    		7.8
    Cardiovascular system
       Hypertension
    		3.4
    		2.6
       Palpitation
    		2.2
    		2
      Vasodilatation
    		3.7
    		1.9
    Digestive system
       Anorexia
    		9.8
    		2.6
       Constipation
    		9.3
    		3.4
       Diarrhea
    		7.7
    		7.2
       Dry mouth
    		14.8
    		5.3
       Nausea
    		30
    		11.8
       Vomiting
    		4.3
    		2.7
    Nervous system
       Abnormal dreams
    		2.9
    		1.4
       Dizziness
    		15.8
    		9.5
       Insomnia
    		17.8
    		9.5
       Libido decreased
    		5.1
    		1.6
       Nervousness
    		7.1
    		5
       Paresthesia
    		2.4
    		1.4
       Somnolence
    		15.3
    		7.5
       Tremor
    		4.7
    		1.6
    Respiratory system
       Yawn
    		3.7
    		0.2
    Skin and appendages
       Sweating (including night sweats)
    		11.4
    		2.9
    Special senses
       Abnormal vision
    		4.2
    		1.6
    Urogenital system
       Abnormal ejaculation/orgasm (men) a
    		9.9
    		0.5
       Anorgasmia (men) a
    		3.6
    		0.1
       Anorgasmia (women) b
    		2
    		0.2
       Impotence (men) a
    		5.3
    		1

    Other Adverse Reactions Observed in Clinical Studies


    Body as a Whole– Photosensitivity reaction, chills

    Cardiovascular System– Postural hypotension, syncope, hypotension, tachycardia

    Digestive System– Gastrointestinal hemorrhage [see Warnings and Precautions (5.4)] , bruxism

    Hemic/Lymphatic System– Ecchymosis [see Warnings and Precautions (5.4)]

    Metabolic/Nutritional– Hypercholesterolemia, weight gain [seeWarnings and Precautions (5.10)], weight loss [see Warnings and Precautions (5.10)]

    Nervous System– Seizures [see Warnings and Precautions (5.8)] , manic reaction [see Warnings and Precautions (5.6)] , agitation, confusion, akathisia, hallucinations, hypertonia, myoclonus, depersonalization, apathy

    Skin and Appendages– Urticaria, pruritus, rash, alopecia

    Special Senses– Mydriasis, abnormality of accommodation, tinnitus, taste perversion

    Urogenital System– Urinary retention, urination impaired, urinary incontinence, urinary frequency increased, menstrual disorders associated with increased bleeding or increased irregular bleeding (e.g., menorrhagia, metrorrhagia)


    Vital Sign Changes


    In placebo-controlled premarketing studies, there were increases in mean blood pressure (see Table 10). Across most indications, a dose-related increase in mean supine systolic and diastolic blood pressure was evident in patients treated with venlafaxine hydrochloride extended-release capsules. Across all clinical studies in MDD, GAD, SAD and PD, 1.4% of patients in the venlafaxine hydrochloride extended-release capsules groups experienced an increase in SDBP of ≥15 mm Hg along with a blood pressure ≥105 mm Hg, compared to 0.9% of patients in the placebo groups. Similarly, 1% of patients in the venlafaxine hydrochloride extended-release capsules groups experienced an increase in SSBP of ≥20 mm Hg with a blood pressure ≥180 mm Hg, compared to 0.3% of patients in the placebo groups.

    Table 10: Final On-therapy Mean Changes from Baseline in Supine Systolic (SSBP) and Diastolic (SDBP) Blood Pressure (mm Hg) in Placebo-controlled Studies
    Indication
       (Duration)
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    ≤75 mg per day
    		>75 mg per day
    		SSBP
    		SDBP
    SSBP
    		SDBP
    		SSBP
    		SDBP
    MDD
        (8 to 12 weeks)
    		-0.28
    		0.37
    		2.93
    		3.56
    		-1.08
    		-0.1
    GAD






         (8 weeks)                             
    		-0.28
    		0.02
    		2.4
    		1.68
    		-1.26
    		-0.92
         (6 months)                           
    		1.27
    		-0.69
    		2.06
    		1.28
    		-1.29
    		-0.74

    SAD
         (12 weeks)
    		-0.29
    		-1.26
    		1.18
    		1.34
    		-1.96
    		-1.22
         (6 months)
    		-0.98
    		-0.49
    		2.51
    		1.96
    		-1.84
    		-0.65
    PD
         (10 to 12 weeks)
    		-1.15
    		0.97
    		-0.36
    		0.16
    		-1.29
    		-0.99

    Venlafaxine hydrochloride extended-release capsules treatment were associated with sustained hypertension (defined as Supine Diastolic Blood Pressure [SDBP] ≥90 mm Hg and ≥10 mm Hg above baseline for three consecutive on-therapy visits (see Table 11). An insufficient number of patients received mean doses of venlafaxine hydrochloride extended-release capsules over 300 mg per day in clinical studies to fully evaluate the incidence of sustained increases in blood pressure at these higher doses.

    Table 11: Sustained Elevations in SDBP in Venlafaxine Hydrochloride Extended-Release Capsules Premarketing Studies
    aMaximum recommended dosage for venlafaxine hydrochloride extended-release capsules is 225 mg once daily.
    Indication
    		Dose Range (mg per day)
    		Incidence (%)
    MDD
    		75 to 375 a
    		19/705 (3)
    GAD
    		37.5 to 225
    		5/1011 (0.5)
    SAD
    		75 to 225
    		5/771 (0.6)
    PD
    		75 to 225
    		9/973 (0.9)

    Venlafaxine hydrochloride extended-release capsules were associated with mean increases in pulse rate compared with placebo in premarketing placebo-controlled studies (see Table 12) [see Warnings and Precautions (5.3, 5.4)] .

    Table 12: Approximate Mean Final On-therapy Increase in Pulse Rate (beats/min) in Venlafaxine Hydrochloride Extended-Release Capsules Premarketing Placebo-controlled Studies (up to 12 Weeks Duration)
    Indication
    (Duration)
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    MDD
        (12 weeks)
    		2
    		1
    GAD
        (8 weeks)
    		2
    		<1
    SAD
       (12 weeks)
    		3
    		1
    PD
       (12 weeks)
    		1
    		<1

    Laboratory Changes


    Serum Cholesterol


    Venlafaxine hydrochloride extended-release capsules were associated with mean final increases in serum cholesterol concentrations compared with mean final decreases for placebo in premarketing MDD, GAD, SAD and PD clinical studies (Table 13).


    Table 13: Mean Final On-therapy Changes in Cholesterol Concentrations (mg/dL) in Venlafaxine Hydrochloride Extended-Release Capsules Premarketing Studies
    Indication
        (Duration)
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    MDD


        (12 weeks)
    		+1.5
    		-7.4
    GAD   





        (8 weeks)

    		+1
    		-4.9

    (6 months)
    		+2.3
    		-7.7
    SAD



        (12 weeks)

    		+7.9

    		-2.9

        (6 months)
    		+5.6
    		-4.2
    PD



        (12 weeks)
    		+5.8
    		-3.7

    Venlafaxine hydrochloride extended-release capsules treatment for up to 12 weeks in premarketing placebo-controlled trials for major depressive disorder was associated with a mean final on-therapy increase in serum cholesterol concentration of approximately 1.5 mg/dL compared with a mean final decrease of 7.4 mg/dL for placebo. Venlafaxine hydrochloride extended-release capsules treatment for up to 8 weeks and up to 6 months in premarketing placebo-controlled GAD trials was associated with mean final on-therapy increases in serum cholesterol concentration of approximately 1 mg/dL and 2.3 mg/dL, respectively while placebo subjects experienced mean final decreases of 4.9 mg/dL and 7.7 mg/dL, respectively. Venlafaxine hydrochloride extended-release capsules treatment for up to 12 weeks and up to 6 months in premarketing placebo-controlled Social Anxiety Disorder trials was associated with mean final on-therapy increases in serum cholesterol concentration of approximately 7.9 mg/dL and 5.6 mg/dL, respectively, compared with mean final decreases of 2.9 and 4.2 mg/dL, respectively, for placebo. Venlafaxine hydrochloride extended-release capsules treatment for up to 12 weeks in premarketing placebo-controlled panic disorder trials was associated with mean final on-therapy increases in serum cholesterol concentration of approximately 5.8 mg/dL compared with a mean final decrease of 3.7 mg/dL for placebo.               


    Patients treated with Effexor (immediate-release) for at least 3 months in placebo-controlled 12-month extension trials had a mean final on-therapy increase in total cholesterol of 9.1 mg/dL compared with a decrease of 7.1 mg/dL among placebo-treated patients. This increase was duration dependent over the study period and tended to be greater with higher doses. Clinically relevant increases in serum cholesterol, defined as 1) a final on-therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL, or 2) an average on-therapy increase in serum cholesterol ≥50 mg/dL from baseline and to a value ≥261 mg/dL, were recorded in 5.3% of venlafaxine-treated patients and 0% of placebo-treated patients.


    Serum Triglycerides

    Venlafaxine hydrochloride extended-release capsules were associated with mean final on-therapy increases in fasting serum triglycerides compared with placebo in premarketing clinical studies of SAD and PD up to 12 weeks (pooled data) and 6 months duration (Table 14).

    Table 14: Mean Final On-therapy Increases in Triglyceride Concentrations (mg/dL) in Venlafaxine Hydrochloride Extended-Release Capsules Premarketing Studies
    Indication
       (Duration)
    		Venlafaxine Hydrochloride Extended-Release Capsules
    		Placebo
    SAD
       (12 weeks)
    		8.2
    		0.4
    SAD


       (6 months)
    		11.8
    		1.8
    PD


       (12 weeks)
    		5.9
    		0.9
    PD


       (6 months)
    		9.3
    		0.3

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during post-approval use of venlafaxine hydrochloride extended-release capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.


    Body as a Whole– Anaphylaxis, angioedema

    Cardiovascular System– QT prolongation, ventricular fibrillation, ventricular tachycardia (including torsade de pointes), takotsubo cardiomyopathy

    Digestive System– Pancreatitis

    Hemic/Lymphatic System– Mucous membrane bleeding [see Warnings and Precautions (5.4)] , blood dyscrasias (including agranulocytosis, aplastic anemia, neutropenia and pancytopenia), prolonged bleeding time, thrombocytopenia

    Metabolic/Nutritional– Hyponatremia [see Warnings and Precautions (5.9)] , Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion [see Warnings and Precautions (5.9)] , abnormal liver function tests, hepatitis, prolactin increased

    Musculoskeletal– Rhabdomyolysis

    Nervous System– Neuroleptic Malignant Syndrome (NMS) [see Warnings and Precautions (5.2)] , serotonergic syndrome [see Warnings and Precautions (5.2)] , delirium, extrapyramidal reactions (including dystonia and dyskinesia), impaired coordination and balance, tardive dyskinesia

    Respiratory, Thoracic and Mediastinal Disorders–Anosmia, dyspnea, hyposmia, interstitial lung disease, pulmonary eosinophilia [see Warnings and Precautions (5.12)]

    Skin and Appendages– Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme

    Special Senses– Angle-closure glaucoma [see Warnings and Precautions (5.5)]

  • 7 DRUG INTERACTIONS

    7.1 Drugs Having Clinically Important Interactions with Venlafaxine Hydrochloride Extended-Release Capsules

    Table 15: Clinically Important Drug Interactions with Venlafaxine Hydrochloride Extended-Release Capsules

    Monoamine Oxidase Inhibitors (MAOI)
    Clinical Impact

    		The concomitant use of SNRIs, including venlafaxine hydrochloride extended-release capsules, with MAOIs increases the risk of serotonin syndrome.
    Intervention

    		Concomitant use of venlafaxine hydrochloride extended-release capsules is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue [see Dosage and Administration (2.11),  Contraindications (4)and Warnings and Precautions (5.2)].
    Other Serotonergic Drugs
    Clinical Impact

    		Concomitant use of venlafaxine hydrochloride extended-release capsules with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St.John's Wort) increases the risk of serotonin syndrome.
    Intervention

    		Monitor for symptoms of serotonin syndrome when venlafaxine hydrochloride extended-release capsules is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of venlafaxine hydrochloride extended-release capsules and/or concomitant serotonergic drugs [see  Dosage and Administration (2.11)and Warnings and Precautions (5.2)].
    Drugs that Interfere with Hemostasis
    Clinical Impact
    		Concomitant use of venlafaxine hydrochloride extended-release capsules with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding. This may be due to the effect of venlafaxine hydrochloride extended-release capsules on the release of serotonin by platelets.
    Intervention

    		Closely monitor for bleeding for patients receiving an antiplatelet or anticoagulant drug when venlafaxine hydrochloride extended-release capsules is initiated or discontinued [see Warnings and Precautions (5.4)] .
    Effect of CYP3A Inhibitors
    Clinical Impact
    		Concomitant use of a CYP3A inhibitor increases the C maxand AUC of venlafaxine and O-desmethylvenlafaxine (ODV) [see Clinical Pharmacology (12.3)] , which may increase the risk of toxicity of venlafaxine hydrochloride extended-release capsules
    Intervention
    		Consider reducing the dose of venlafaxine hydrochloride extended-release capsules.
    CYP2D6 Substrates
    Clinical Impact
    		Concomitant use of venlafaxine hydrochloride extended-release capsules increases C maxand AUC of a CYP2D6 substrate, which may increase the risk of toxicity of the CYP2D6 substrate [see Clinical Pharmacology (12.3)] .
    Intervention
    		Consider reduction in dose of concomitant CYP2D6 substrates.

    7.2 Other Drug Interactions with Venlafaxine Hydrochloride Extended-Release Capsules

    Central Nervous System (CNS)-Active Drugs


    The risk of using venlafaxine concomitantly with other CNS-active drugs (including alcohol) has not been systematically evaluated. Consequently, caution is advised when venlafaxine hydrochloride extended-release capsules are taken concomitantly in combination with other CNS-active drugs.


    Weight Loss Agents


    Concomitant use of venlafaxine hydrochloride extended-release capsules and weight loss agents is not recommended. The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Venlafaxine hydrochloride extended-release capsules are not indicated for weight loss alone or in combination with other products.


    Laboratory Test Interference


    False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine due to lack of specificity of the screening tests. False-positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Pregnancy Exposure Registry


    There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants, including venlafaxine hydrochloride extended-release capsules, during pregnancy. Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/clinical-and-research­programs/pregnancyregistry/antidepressants/.


    Risk Summary

    Based on data from published observational studies, exposure to SNRIs, particularly in the month before delivery, has been associated with a less than 2-fold increase in the risk of postpartum hemorrhage [see Warnings and Precautions (5.4) and Clinical Considerations].

    Available data from published epidemiologic studies on venlafaxine use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or adverse fetal outcomes (see Data). Available data from observational studies with venlafaxine have identified a potential increased risk for preeclampsia when used during mid to late pregnancy; exposure to SNRIs near delivery may increase the risk for postpartum hemorrhage (see Clinical Considerations). There are risks associated with untreated depression in pregnancy and poor neonatal adaptation in newborns with exposure to SNRIs, including venlafaxine hydrochloride extended-release capsules, during pregnancy (see Clinical Considerations).


    In animal studies, there was no evidence of malformations or fetotoxicity following administration of venlafaxine during organogenesis at doses up to 2.5 times (rat) or 4 times (rabbit) the maximum recommended human daily dose on a mg/m 2basis. Postnatal mortality and decreased pup weights were observed following venlafaxine administration to pregnant rats during gestation and lactation at 2.5 times (mg/m 2) the maximum human daily dose.


    The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.


    Clinical Considerations


    Disease-Associated Maternal and/or Embryo/Fetal Risk


    Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants. This finding is from a prospective, longitudinal study that followed 201 pregnant women with a history of major depression who were euthymic and taking antidepressants at the beginning of pregnancy. Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum.

    Maternal Adverse Reactions


    Exposure to venlafaxine in mid to late pregnancy may increase the risk for preeclampsia, and exposure to venlafaxine in the month before delivery may be associated with an increased risk of postpartum hemorrhage [see Warnings and Precautions (5.4)].

    Fetal/Neonatal Adverse Reactions


    Neonates exposed to SNRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremors, jitteriness, irritability, and constant crying. These findings are consistent with either a direct toxic effect of SNRIs or possibly a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome [seeWarnings and Precautions (5.2)]. Monitor neonates who were exposed to venlafaxine hydrochloride extended-release capsules in the third trimester of pregnancy for drug discontinuation syndrome (see Data).


    Data

    Human Data


    Published epidemiological studies of pregnant women exposed to venlafaxine have not established an increased risk of major birth defects, miscarriage or other adverse developmental outcomes. Methodological limitations may both fail to identify true findings and also identify findings that are not true.


    Retrospective cohort studies based on claims data have shown an association between venlafaxine use and preeclampsia, compared to depressed women who did not take an antidepressant during pregnancy. One study that assessed venlafaxine exposure in the second trimester or first half of the third trimester and preeclampsia showed an increased risk compared to unexposed depressed women (adjusted [adj] RR 1.57, 95% confidence interval [CI] 1.29 to 1.91). Preeclampsia was observed at venlafaxine doses equal to or greater than 75 mg per day and a duration of treatment >30 days. Another study that assessed venlafaxine exposure in gestational weeks 10 to 20 and preeclampsia showed an increased risk at doses equal to or greater than 150 mg per day. Available data are limited by possible outcome misclassification and possible confounding due to depression severity and other confounders.


    Retrospective cohort studies based on claims data have suggested an association between venlafaxine use near the time of delivery or through delivery and postpartum hemorrhage. One study showed an increased risk for postpartum hemorrhage when venlafaxine exposure occurred through delivery, compared to unexposed depressed women (adj RR 2.24 [95% CI 1.69 to 2.97]). There was no increased risk in women who were exposed to venlafaxine earlier in pregnancy. Limitations of this study include possible confounding due to depression severity and other confounders. Another study showed an increased risk for postpartum hemorrhage when SNRI exposure occurred for at least 15 days in the last month of pregnancy or through delivery, compared to unexposed women (adj RR 1.64 to 1.76). The results of this study may be confounded by the effects of depression.

    Animal Data


    Venlafaxine did not cause malformations in offspring of rats or rabbits given doses up to 2.5 times (rat) or 4 times (rabbit) the maximum recommended human daily dose on a mg/m 2basis. However, in rats, there was a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation, when dosing began during pregnancy and continued until weaning. The cause of these deaths is not known. These effects occurred at 2.5 times (mg/m 2) the maximum human daily dose. The no effect dose for rat pup mortality was 0.25 times the human dose on a mg/m 2basis.


    When desvenlafaxine succinate, the major metabolite of venlafaxine, was administered orally to pregnant rats and rabbits during the period of organogenesis at doses up to 300 mg/kg/day and 75 mg/kg/day, respectively, no fetal malformations were observed. These doses were associated with a plasma exposure (AUC) 19 times (rats) and 0.5 times (rabbits) the AUC exposure at an adult human dose of 100 mg per day. However, fetal weights were decreased and skeletal ossification was delayed in rats in association with maternal toxicity at the highest dose, with an AUC exposure at the no-effect dose that is 4.5-times the AUC exposure at an adult human dose of 100 mg per day.

    8.2 Lactation

    Risk Summary


    Data from published literature report the presence of venlafaxine and its active metabolite in human milk and have not shown adverse reactions in breastfed infants (see Data). There are no data on the effects of venlafaxine on milk production.


    The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for venlafaxine hydrochloride extended-release capsules and any potential adverse effects on the breastfed child from venlafaxine hydrochloride extended-release capsules or from the underlying maternal condition.


    Data


    In a lactation study conducted in 11 breastfeeding women (at a mean of 20.1 months post-partum) who were taking a mean daily dose of 194.3 mg of venlafaxine and in a lactation study conducted in 6 breastfeeding women who were taking a daily dose of 225 mg to 300 mg of venlafaxine (at a mean of 7 months post-partum), the estimated mean relative infant dose was 8.1% and 6.4% based on the sum of venlafaxine and its major metabolite, desvenlafaxine. No adverse reactions were seen in the infants.


    8.4 Pediatric Use

    Safety and effectiveness of venlafaxine hydrochloride extended-release capsules in pediatric patients have not been established.


    Two placebo-controlled trials in 766 pediatric patients with MDD and two placebo-controlled trials in 793 pediatric patients with GAD have been conducted with venlafaxine hydrochloride extended-release capsules, and the data were not sufficient to support use in pediatric patients.


    In the studies conducted in pediatric patients ages 6 to 17 years, the occurrence of blood pressure and cholesterol increases was considered to be clinically relevant in pediatric patients and was similar to that observed in adult patients [seeWarnings and Precautions (5.3),Adverse Reactions (6.1)].The following adverse reactions were also observed in pediatric patients: abdominal pain, agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.


    Although no studies have been designed to primarily assess venlafaxine hydrochloride extended-release capsules impact on the growth, development, and maturation of children and adolescents, the studies that have been done suggest that venlafaxine hydrochloride extended-release capsules may adversely affect weight and height [see Warnings and Precautions (5.10, 5.11)] . Decreased appetite and weight loss were observed in placebo-controlled studies of pediatric patients 6 to 17 years.


    In pediatric clinical studies, the adverse reaction, suicidal ideation, was observed. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric patients [see Boxed Warning, Warnings and Precautions (5.1)] .

    8.5 Geriatric Use

    The percentage of patients in clinical studies for venlafaxine hydrochloride extended-release capsules for MDD, GAD, SAD, and PD who were 65 years of age or older are shown in Table 16.


    Table 16: Percentage (and Number of Patients Studied) of Patients 65 Years of Age and Older by Indication a
    aIn addition, in the premarketing assessment of Effexor (immediate-release), 12% (357/2,897) of patients were ≥ 65 years of age.
    Indication
    		Venlafaxine Hydrochloride Extended-Release Capsules
    MDD
    		4 (14/357)
    GAD
    		6 (77/1,381)
    SAD
    		1 (10/819)
    PD
    		2 (16/1,001)

     No overall differences in effectiveness or safety were observed between geriatric patients and younger patients, and other reported clinical experience generally has not identified differences in response between the elderly and younger patients. However, greater sensitivity of some older individuals cannot be ruled out. SSRIs and SNRIs, including venlafaxine hydrochloride extended-release capsules, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see Warnings and Precautions (5.9)] .


    The pharmacokinetics of venlafaxine and ODV are not substantially altered in the elderly [seeClinical Pharmacology (12.3)](see Figure 1). No dose adjustment is recommended for the elderly on the basis of age alone, although other clinical circumstances, some of which may be more common in the elderly, such as renal or hepatic impairment, may warrant a dose reduction [see Dosage and Administration (2.8, 2.9)] .


    8.6 Hepatic Impairment

    Dosage adjustment is recommended in patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B), or severe (Child-Pugh Class C) hepatic impairment or hepatic cirrhosis [see  Dosage and Administration (2.8)and Clinical Pharmacology (12.3)] .

    8.7 Renal Impairment

    Dosage adjustment is recommended in patients with mild (CLcr= 60 to 89 mL/min), moderate (CLcr= 30 to ­59 mL/min), or severe (CLcr < 30 mL/min) renal impairment, and in patients undergoing hemodialysis [see  Dosage and Administration (2.9)and Clinical Pharmacology (12.3)].

  • 9 DRUG ABUSE AND DEPENDENCE

    9.1 Controlled Substance

    Venlafaxine hydrochloride extended-release capsule contains venlafaxine which is not a controlled substance.

    9.2 Abuse

    Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.


    While venlafaxine has not been systematically studied in clinical studies for its potential for abuse, there was no indication of drug-seeking behavior in the clinical studies. However, it is not possible to predict on the basis of premarketing experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, providers should carefully evaluate patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse of venlafaxine (e.g., development of tolerance, incrementation of dose, drug-seeking behavior).

    9.3 Dependence

    Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.


    In vitrostudies revealed that venlafaxine has virtually no affinity for opiate, benzodiazepine, phencyclidine (PCP), or N-methyl-D-aspartic acid (NMDA) receptors.


    Venlafaxine was not found to have any significant CNS stimulant activity in rodents. In primate drug discrimination studies, venlafaxine showed no significant stimulant or depressant abuse liability.


    Discontinuation effects have been reported in patients receiving venlafaxine [see  Dosage and Administration (2.10)and Warnings and Precautions (5.7)].

  • 10 OVERDOSAGE

    Human Experience


    During the premarketing evaluations of venlafaxine hydrochloride extended-release capsules (for MDD, GAD, SAD, and PD) and venlafaxine hydrochloride (for MDD), there were twenty reports of acute overdosage with venlafaxine hydrochloride (6 and 14 reports in venlafaxine hydrochloride extended-release capsules and venlafaxine hydrochloride patients, respectively), either alone or in combination with other drugs and/or alcohol.  


    Somnolence was the most commonly reported symptom. Among the other reported symptoms were paresthesia of all four limbs, moderate dizziness, nausea, numb hands and feet, and hot-cold spells 5 days after the overdose. In most cases, no signs or symptoms were associated with overdose. The majority of the reports involved ingestion in which the total dose of venlafaxine taken was estimated to be no more than several-fold higher than the usual therapeutic dose. One patient who ingested 2.75 g of venlafaxine was observed to have two generalized convulsions and a prolongation of QTc to 500 msec, compared with 405 msec at baseline. Mild sinus tachycardia was reported in two of the other patients.


    Actions taken to treat the overdose included no treatment, hospitalization and symptomatic treatment, and hospitalization plus treatment with activated charcoal. All patients recovered.


    In postmarketing experience, overdose with venlafaxine has occurred predominantly in combination with alcohol and/or other drugs. The most commonly reported events in overdosage include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported.


    Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher preexisting burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristic(s) of venlafaxine-treated patients, is not clear. Prescriptions for venlafaxine hydrochloride extended-release capsules should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.


    Management of Overdosage


    No specific antidotes for venlafaxine hydrochloride extended-release capsules are known. In managing overdosage, consider the possibility of multiple drug involvement. Consider contacting a Poison Center (1-800-222-1222) or a medical toxicologist for overdosage management recommendations for venlafaxine hydrochloride extended-release capsules.

  • 11 DESCRIPTION


    Venlafaxine hydrochloride extended-release capsule, USP is an extended-release capsule for once-a-day oral administration that contains venlafaxine hydrochloride USP, a serotonin and norepinephrine reuptake inhibitor (SNRI).

    Venlafaxine is designated (R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[α- [(dimethylamino)methyl]-p-­methoxybenzyl] cyclohexanol hydrochloride and has the molecular formula of C 17H 27NO 2HCl. Its molecular weight is 313.86. The structural formula is shown as follows:



    Chemical Structure




    Venlafaxine hydrochloride USP is a white or almost white crystalline powder, with a solubility of 572 mg/mL in water (adjusted to ionic strength of 0.2 M with sodium chloride). Its octanol:water (0.2 M sodium chloride) partition coefficient is 0.43.

    Drug release is controlled by diffusion through the coating membrane on the spheroids and is not pH-dependent. Capsules contain venlafaxine hydrochloride USP equivalent to 37.5 mg, 75 mg, or 150 mg venlafaxine. Inactive ingredients consist of ethyl cellulose, hypromellose, sugar spheres, and talc. The empty hard gelatin capsule shells contain iron oxide red, gelatin, titanium dioxide, and sodium lauryl sulphate. In addition, the 37.5 mg empty hard gelatin capsule shells contain iron oxide black. The capsules are printed with edible ink containing black iron oxide and shellac.

    Meets the USP Dissolution Test - 4

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The mechanism of action of venlafaxine in the treatment of MDD, GAD, SAD, and PD is unclear, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.

    12.2 Pharmacodynamics

    In vitrostudies have demonstrated that venlafaxine and its active metabolite, O-desmethylvenlafaxine (ODV), are potent and selective inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake. Venlafaxine and ODV have no significant affinity for muscarinic-cholinergic, H 1-histaminergic, or α 1-adrenergic receptors in vitro. Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs. Venlafaxine and ODV do not possess monoamine oxidase (MAO) inhibitory activity.


    Cardiac Electrophysiology


    The effect of venlafaxine on the QT interval was evaluated in a randomized, double-blind, placebo- and positive-controlled three-period crossover thorough QT study in 54 healthy adult subjects. No significant QT prolongation effect of venlafaxine at 450 mg (2 times the maximum recommended dosage) was detected.

    12.3 Pharmacokinetics

    Venlafaxine and ODV steady-state concentrations are reached within 3 days. Venlafaxine and ODV exhibited linear kinetics over the dosage range of 75 to 450 mg per day (0.33 to 2 times the maximum recommended dosage). Time of administration (AM versus PM) did not affect the pharmacokinetics of venlafaxine and ODV from the 75 mg venlafaxine hydrochloride extended-release capsule.


    Absorption


    Venlafaxine is well absorbed. On the basis of mass balance studies, at least 92% of a single oral dose of venlafaxine is absorbed. The absolute bioavailability of venlafaxine is approximately 45%.


    Administration of venlafaxine hydrochloride extended-release capsules (150 mg once daily) generally resulted in lower C maxand later T maxvalues than for venlafaxine hydrochloride administered twice daily (Table 17). When equal daily doses of venlafaxine were administered as either an immediate-release tablet or the extended-release capsule, the exposure to both venlafaxine and ODV was similar for the two treatments, and the fluctuation in plasma concentrations was slightly lower with the venlafaxine hydrochloride extended-release capsule. Therefore, venlafaxine hydrochloride extended-release capsules provides a slower rate of absorption, but the same extent of absorption compared with the immediate-release tablet.


    Table 17: Comparison of C maxand T maxValues for Venlafaxine and ODV Following Oral Administration of Venlafaxine Hydrochloride Extended-Release Capsules and Effexor (Immediate-Release)



    		Venlafaxine
    		ODV
    C max
    (ng/mL)
    		T max
    (h)
    		C max
    (ng/mL)
    		T max
    (h)
    Venlafaxine Hydrochloride Extended-Release Capsules (150 mg once daily)
    		150
    		5.5
    		260
    		9
    Venlafaxine Hydrochloride (75 mg twice daily)
    		225
    		2
    		290
    		3

    Effect of Food


    Food did not affect the bioavailability of venlafaxine or its active metabolite, ODV.


    Distribution


    Venlafaxine is 27% and ODV is 30% bound to plasma proteins. The apparent volume of distribution at steady-state is 7.5 ± 3.7 L/kg for venlafaxine and 5.7 ± 1.8 L/kg for ODV.


    Elimination


    Mean ± SD plasma apparent clearance at steady-state is 1.3 ± 0.6 L/h/kg for venlafaxine and 0.4 ± 0.2 L/h/kg for ODV. The apparent elimination half-life is 5 ± 2 hours for venlafaxine and 11 ± 2 hours for ODV.


    Metabolism

    Following absorption, venlafaxine undergoes extensive presystemic metabolism in the liver, primarily to ODV, but also to N-desmethylvenlafaxine, N,O-didesmethylvenlafaxine, and other minor metabolites. In vitrostudies indicate that the formation of ODV is catalyzed by CYP2D6; this has been confirmed in a clinical study showing that patients with low CYP2D6 levels (poor metabolizers) had increased levels of venlafaxine and reduced levels of ODV compared to people with normal CYP2D6 levels (extensive metabolizers) (see Figure 1).

    Excretion


    Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).


    Specific Populations


    The effect of intrinsic patient factors on the pharmacokinetics of venlafaxine and its active metabolite ODV is presented in Figure 1.


    Figure 1: Pharmacokinetics of Venlafaxine and Active Metabolite O-desmethylvenlafaxine (ODV) in Special Populations


    figure

    ODV=O-desmethylvenlafaxine; AUC=area under the curve; C max=peak plasma concentrations.

    *Similar effect is expected with strong CYP2D6 inhibitors.


    Drug Interaction Studies


    Clinical Studies

    Effect of Other Drugs on Venlafaxine Hydrochloride Extended-Release Capsules and Active Metabolite ODV


    The effects of other drugs on the exposure of venlafaxine and ODV are summarized in Figure 2.


    Figure 2: Effect of Other Drugs on the Pharmacokinetics of Venlafaxine and Active Metabolite O-desmethylvenlafaxine (ODV)


    figure

    ODV=O-desmethylvenlafaxine; AUC=area under the curve; C max=peak plasma concentrations; EM’s=extensive metabolizers; PM’s=poor metabolizers.


    Effect of Venlafaxine Hydrochloride Extended-Release Capsules on Other Drugs


    The effects of Venlafaxine Hydrochloride Extended-Release Capsules on the exposure of other drugs are summarized in Figure 3.


    Figure 3: Effect of Venlafaxine on the Pharmacokinetics of Interacting Drugs and their Active Metabolites


    figure

    AUC=area under the curve; C max=peak plasma concentrations; OH=hydroxyl.

    *Data for 2-OH desipramine were not plotted to enhance clarity; the fold change and 90% CI for C maxand AUC of 2-­OH desipramine were 6.6 (5.5, 7.9) and 4.4 (3.8, 5.0), respectively.

    Note:*Administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Tumors were not increased by venlafaxine treatment in mice or rats. Venlafaxine was given by oral gavage to mice for 18 months at doses up to 120 mg/kg per day, which was 1.7 times the maximum recommended human dose on a mg/m 2basis. Venlafaxine was also given to rats by oral gavage for 24 months at doses up to 120 mg/kg per day. In rats receiving the 120 mg/kg dose, plasma concentrations of venlafaxine at necropsy were 1 times (male rats) and 6 times (female rats) the plasma concentrations of patients receiving the maximum recommended human dose. Plasma levels of the ODV were lower in rats than in patients receiving the maximum recommended dose. ODV, the major human metabolite of venlafaxine, administered by oral gavage to mice and rats for 2 years did not increase the incidence of tumors in either study. Mice received ODV at dosages up to 500/300 mg/kg/day (dosage lowered after 45 weeks of dosing). The exposure at the 300 mg/kg/day dose is 9 times that of a human dose of 225 mg/day. Rats received ODV at dosages up to 300 mg/kg/day (males) or 500 mg/kg/day (females). The exposure at the highest dose is approximately 8 (males) or 11 (females) times that of a human dose of 225 mg/day.

    Mutagenesis

    Venlafaxine and the major human metabolite, ODV, were not mutagenic in the Ames reverse mutation assay in Salmonellabacteria or the Chinese hamster ovary/HGPRT mammalian cell forward gene mutation assay. Venlafaxine was also not mutagenic or clastogenic in the in vitroBALB/c-3T3 mouse cell transformation assay, the sister chromatid exchange assay in cultured Chinese hamster ovary cells, or in the in vivochromosomal aberration assay in rat bone marrow. ODV was not clastogenic in the in vitroChinese hamster ovary cell chromosomal aberration assay or in the in vivochromosomal aberration assay in rats.

    Impairment of Fertility

    Reproduction and fertility studies of venlafaxine in rats showed no adverse effects of venlafaxine on male or female fertility at oral doses of up to 2 times the maximum recommended human dose of 225 mg/day on a mg/m 2basis. However, when desvenlafaxine succinate, the major human metabolite of venlafaxine, was administered orally to male and female rats, fertility was reduced at the high dose of 300 mg/kg/day, which is 10 (males) and 19 (females) times the AUC exposure at an adult human dose of 100 mg per day. There was no effect on fertility at 100 mg/kg/day, which is 3 (males) or 5 (females) times the AUC exposure at an adult human dose of 100 mg per day. These studies did not address reversibility of the effect on fertility. The relevance of these findings to humans is not known.

  • 14 CLINICAL STUDIES

    14.1 Major Depressive Disorder

    The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Major Depressive Disorder (MDD) was established in two placebo-controlled, short-term (8 weeks for study 1; 12 weeks for study 2), flexible-dose studies, with doses starting at 75 mg per day and ranging to 225 mg per day in adult outpatients meeting DSM-III-R or DSM-IV criteria for MDD. In moderately depressed outpatients, the initial dose of venlafaxine was 75 mg per day. In both studies, venlafaxine hydrochloride extended-release capsules demonstrated superiority over placebo on the primary efficacy measure defined as change from baseline in the HAM-D-21 total score to the endpoint visit, venlafaxine hydrochloride extended-release capsules also demonstrated superiority over placebo on the key secondary efficacy endpoint, the Clinical Global Impressions (CGI) Severity of Illness scale. Examination of gender subsets of the population studied did not reveal any differential responsiveness on the basis of gender.


    A 4-week study of inpatients meeting DSM-III-R criteria for MDD with melancholia utilizing venlafaxine hydrochloride in a range of 150 to 375 mg per day (divided in a three-times-a-day schedule) demonstrated superiority of venlafaxine hydrochloride over placebo based on the HAM-D-21 total score. The mean dose in completers was 350 mg per day (study 3).


    In a longer-term study, adult outpatients with MDD who had responded during an 8-week open-label study on venlafaxine hydrochloride extended-release capsules (75, 150, or 225 mg, once daily every morning) were randomized to continuation of their same venlafaxine hydrochloride extended-release capsules dose or to placebo, for up to 26 weeks of observation for relapse. Response during the open-label phase was defined as a CGI Severity of Illness item score of ≤3 and a HAM-D-21 total score of ≤10 at the day 56 evaluation. Relapse during the double-blind phase was defined as follows: (1) a reappearance of major depressive disorder as defined by DSM-IV criteria and a CGI Severity of Illness item score of ≥4 (moderately ill), (2) 2 consecutive CGI Severity of Illness item scores of ≥4, or (3) a final CGI Severity of Illness item score of ≥4 for any patient who withdrew from the study for any reason. Patients receiving continued venlafaxine hydrochloride extended-release capsules treatment experienced statistically significantly lower relapse rates over the subsequent 26 weeks compared with those receiving placebo (study 4).


    In a second longer term trial, adult outpatients with MDD, recurrent type, who had responded (HAM-D-21 total score ≤12 at the day 56 evaluation) and continued to be improved [defined as the following criteria being met for days 56 through 180: (1) no HAM-D-21 total score ≥20; (2) no more than 2 HAM-D-21  total scores >10, and (3) no single CGI Severity of Illness item score ≥4 (moderately ill)] during an initial 26 weeks of treatment on venlafaxine hydrochloride [100 to 200 mg per day, on a twice daily schedule] were randomized to continuation of their same venlafaxine hydrochloride dose or to placebo. The follow-up period to observe patients for relapse, defined as a CGI Severity of Illness item score ≥4, was for up to 52 weeks. Patients receiving continued venlafaxine hydrochloride treatment experienced statistically significantly lower relapse rates over the subsequent 52 weeks compared with those receiving placebo (study 5).

    Table 18:  Primary Efficacy Results for Studies in Major Depressive Disorder in Adults (Studies 1, 2, 3)
    SD=standard deviation; LS Mean=least-squares mean; CI=confidence interval.
    aDifference (drug minus placebo) in least-squares mean change from baseline.
    * Doses statistically significantly superior to placebo.
    Study
    Number
    		Treatment
    Group
    		Primary Efficacy Measure: HAM-D Score
    Mean Baseline Score (SD)
    		LS Mean Change from Baseline
    		Placebo Subtracted Difference a(95%CI)
    Study 1
    		Venlafaxine Hydrochloride Extended-Release Capsules (75 to 225 mg/day)*
    		          24.5
    		       -11.7
    		    -4.45(-6.66,-2.25)
    Placebo
    		          23.6
    		        -7.24
    		                  -
    Study 2
    		Venlafaxine Hydrochloride Extended-Release Capsules (75 to 225 mg/day)*
    		          24.5
    		       -15.11
    		      -6.4(-8.45,-4.34)

    Placebo
    		         24.9
    		         -8.71

    Study 3
    		Effexor (immediate release) (150 to 375 mg/day)*
    		        28.2 (0.5)
    		         -14.9
    		        -10.2 (-14.4,-6)

    Placebo
    		        28.6 (0.6)
    		          -4.7
    		                 -

    14.2 Generalized Anxiety Disorder

    The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Generalized Anxiety Disorder (GAD) was established in two 8-week, placebo-controlled, fixed-dose studies (75 to 225 mg per day), one 6-month, placebo-controlled, flexible-dose study (75 to 225 mg per day), and one 6-month, placebo-controlled, fixed-dose study (37.5, 75, and 150 mg per day) in adult outpatients meeting DSM-IV criteria for GAD.  


    In one 8-week study, venlafaxine hydrochloride extended-release capsules demonstrated superiority over placebo for the 75, 150, and 225 mg per day doses as measured by the Hamilton Rating Scale for Anxiety (HAM-A) total score, both the HAM-A anxiety and tension items, and the Clinical Global Impressions (CGI) scale. However, the 75 and 150 mg per day doses were not as consistently effective as the highest dose (study 1). A second 8-week study evaluating doses of 75 and 150 mg per day and placebo showed that both doses were more effective than placebo on some of these same outcomes; however, the 75 mg per day dose was more consistently effective than the 150 mg per day dose (study 2). A dose-response relationship for effectiveness in GAD was not clearly established in the 75 to 225 mg per day dose range studied.


    Two 6-month studies, one evaluating venlafaxine hydrochloride extended-release capsules doses of 37.5, 75, and 150 mg per day (study 3) and the other evaluating venlafaxine hydrochloride extended-release capsules doses of 75 to 225 mg per day (study 4), showed that daily doses of 75 mg or higher were more effective than placebo on the HAM-A total, both the HAM-A anxiety and tension items, and the CGI scale during 6 months of treatment. While there was also evidence for superiority over placebo for the 37.5 mg per day dose, this dose was not as consistently effective as the higher doses. 

    Examination of gender subsets of the population studied did not reveal any differential responsiveness on the basis of gender.  

    Table 19: Primary Efficacy Results for Studies in Generalized Anxiety Disorder in Adults (Studies 1, 2, 3, 4)
    SD=standard deviation; SE=standard error; LS Mean=least-squares mean; CI=confidence interval.
    a Difference (drug minus placebo) in least-squares mean change from baseline.
    * Doses statistically significantly superior to placebo.
    Study Number
    		Treatment Group
    		Primary Efficacy Measure: HAM-A Score
    Mean Baseline Score (SD)
    		LS Mean Change from Baseline (SE)*
    		Placebo Subtracted Difference a
    (95% CI)
    Study 1
    		Venlafaxine Hydrochloride Extended-Release Capsules 75 mg

    		24.7
    		-11.1 (0.95)
    		-1.5 (-3.8, 0.8)
    Venlafaxine Hydrochloride Extended-Release Capsules 150 mg


    24.5

    -11.7 (0.87)

    -2.2 (-4.5, 0.1)
    Venlafaxine Hydrochloride Extended-Release Capsules 225 mg  


    23.6

    -12.1 (0.81)

    -2.6 (-4.9, -0.3)
    Placebo
    		24.1
    		-9.5 (0.85)

    Study 2
    		Venlafaxine Hydrochloride Extended-Release Capsules 75 mg

    23.7
    		-10.6 (0.82)
    		-2.6 (-4.6, -0.5)

    Venlafaxine Hydrochloride Extended-Release Capsules 150 mg
    		23
    		-9.8 (0.86)
    		-1.7 (-3.8, 0.3)
    Placebo
    		23.7
    		-8 (0.73)

    Study 3
    		Venlafaxine Hydrochloride Extended-Release Capsules 37.5 mg

    		26.6 (0.4)
    		-13.8
    		-2.8 (-5.1, -0.6)

    Venlafaxine Hydrochloride Extended-Release Capsules 75 mg

    		26.3 (0.4)
    		-15.5
    		-4.6 (-6.9, -2.3)

    Venlafaxine Hydrochloride Extended-Release Capsules 150 mg

    		26.3 (0.4)
    		-16.4
    		-5.5 (-7.8, -3.1)

    Placebo
    		26.7 (0.5)
    		-11
    		-
                  Study 4
    		Venlafaxine Hydrochloride Extended-Release Capsules 75 to 225 mg
    		25
    		-13.4 (0.79)
    		-4.7 (-6.6, -2.9)
    Placebo
    		24.9
    		-8.7 (0.7)

    14.3 Social Anxiety Disorder (Also Known as Social Phobia)

    The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Social Anxiety Disorder (SAD) was established in four double-blind, parallel-group, 12-week, multicenter, placebo-controlled, flexible-dose studies (studies 1 to 4) and one double-blind, parallel-group, 6-month, placebo-controlled, fixed/flexible-dose study, which included doses in a range of 75 to 225 mg per day in adult outpatients meeting DSM-IV criteria for SAD (study 5).


    In these five studies, venlafaxine hydrochloride extended-release capsules were statistically significantly more effective than placebo on change from baseline to endpoint on the Liebowitz Social Anxiety Scale (LSAS) total score. There was no evidence for any greater effectiveness of the 150 to 225 mg per day group compared to the 75 mg per day group in the 6-month study.


    Examination of subsets of the population studied did not reveal any differential responsiveness on the basis of gender. There was insufficient information to determine the effect of age or race on outcome in these studies.

    Table 20: Primary Efficacy Results for Studies in Social Anxiety Disorder in Adults (Studies 1, 2, 3, 4, 5)
    SD=standard deviation; SE=standard error; LS Mean=least-squares mean; CI=confidence interval.
    a Difference (drug minus placebo) in least-squares mean change from baseline.
    * Doses statistically significantly superior to placebo.
    Study Number
    		Treatment Group
    		Primary Efficacy Measure: LSAS Score
    Mean Baseline
    Score (SD)
    		LS Mean Change from Baseline (SE)
    		Placebo Subtracted
    Difference a(95% CI)
    Study 1
    		Venlafaxine Hydrochloride Extended-Release Capsules (75 to 225 mg) *
    		91.1
    		-31 (2.22)
    		11.2 (-5.3, -17.1)
    Placebo
    		86.7
    		-19.9 (2.22)
    		-
    Study 2
    		Venlafaxine Hydrochloride Extended-Release Capsules (75 to 225 mg) *
    		90.8
    		-32.8 (2.69)
    		-10.7 (-3.7, -17.6)
    Placebo
    		87.4
    		-22.1 (2.66)
    		-
    Study 3
    		Venlafaxine Hydrochloride Extended-Release Capsules (75 to 225 mg) *
    		83.2
    		-36 (2.35)
    		-16.9 (-22.6, -11.2)
    Placebo
    		83.6
    		-19.1 (2.4)
    		-12.7 (-6.5, -19)
    Study 4
    		Venlafaxine Hydrochloride Extended-Release Capsules (75 to 225 mg) *
    		86.2
    		-35 (2.64)
    		-14.6 (-21.8, -7.4)
    Placebo
    		86.1
    		-22.2 (2.47)

    Study 5
    		Venlafaxine Hydrochloride Extended-Release Capsules 75 mg
    		91.8
    		-38.1 (3.16)
    		-14.6 (-21.8, -7.4)
    Venlafaxine Hydrochloride Extended-Release Capsules (150 to 225 mg) *
    		86.2
    		-37.6 (3.05)
    		-14.1 (-21.3, -6.9)
    Placebo
    		89.3
    		-23.5 (3.08)


    14.4 Panic Disorder

    The efficacy of venlafaxine hydrochloride extended-release capsules as a treatment for Panic Disorder (PD) was established in two double-blind, 12-week, multicenter, placebo-controlled studies in adult outpatients meeting DSM-IV criteria for PD, with or without agoraphobia. Patients received fixed doses of 75 or 150 mg per day in one study (study 1) and 75 or 225 mg per day in the other study (study 2).


    Efficacy was assessed on the basis of outcomes in three variables: (1) percentage of patients free of full-symptom panic attacks on the Panic and Anticipatory Anxiety Scale (PAAS); (2) mean change from baseline to endpoint on the Panic Disorder Severity Scale (PDSS) total score; and (3) percentage of patients rated as responders (much improved or very much improved) on the Clinical Global Impressions (CGI) Improvement scale. In these two studies, venlafaxine hydrochloride extended-release capsules were statistically significantly more effective than placebo (for each fixed dose) on all three endpoints, but a dose-response relationship was not clearly established.


    Examination of subsets of the population studied did not reveal any differential responsiveness on the basis of gender. There was insufficient information to determine the effect of age or race on outcome in these studies.


    In a longer term study (study 3), adult outpatients meeting DSM-IV criteria for PD who had responded during a 12-week open phase with venlafaxine hydrochloride extended-release capsules (75 to 225 mg per day) were randomly assigned to continue the same venlafaxine hydrochloride extended-release capsules dose (75, 150, or 225 mg) or switch to placebo for observation for relapse under double-blind conditions. Response during the open phase was defined as ≤ 1 full-symptom panic attack per week during the last 2 weeks of the open phase and a CGI Improvement score of 1 (very much improved) or 2 (much improved). Relapse during the double-blind phase was defined as having 2 or more full-symptom panic attacks per week for 2 consecutive weeks or having discontinued due to loss of effectiveness as determined by the investigators during the study. Randomized patients were in response status for a mean time of 34 days prior to being randomized. In the randomized phase following the 12-week open-label period, patients receiving continued venlafaxine hydrochloride extended-release capsules experienced a statistically significantly longer time to relapse.

    Table 21: Primary Efficacy Results for Studies in Panic Disorder in Adults (Studies 1 and 2)
    aOdds ratio (drug to placebo) in terms of probability of free of full-symptom panic attacks based on logistic regression model.
    95% CI: 95% confidence interval without adjusting for multiple dose arms.  
    *Doses statistically significantly superior to placebo.
    Study
    Treatment Group Number
    		Primary Efficacy Measure: Whether Free of Full-symptom Panic Attacks
    Percent of Patients Free of Full Symptom Panic Attack
    		Adjusted Odds Ratio ato Placebo
    		Adjusted Odds Ratio a95% Confidence Interval
    Study 1
    		Venlafaxine Hydrochloride Extended-Release Capsules 75 mg *
    		54.1% (85/157)
    		2. 268
    		(1.43, 3.59)
    Venlafaxine Hydrochloride Extended-Release Capsules 150 mg *
    		61.4% (97/158)
    		3.035
    		(1.91, 4.82)
    Placebo
    		34.4% (53/154)
    		--
    		--
    Study 2
    		Venlafaxine Hydrochloride Extended-Release Capsules 75 mg *
    		64.1% (100/156)
    		2.350
    		(1.46, 3.78)
    Venlafaxine Hydrochloride Extended-Release Capsules 225 mg *
    		70% (112/160)
    		2.890
    		(1.80, 4.64)
    Placebo
    		46.5% (73/157)
    		--
    		--

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Venlafaxine Hydrochloride Extended-Release Capsules USP, 37.5 mgare white to off white spherical to oval pellets filled in empty hard gelatin capsule shell (size ‘3’) of opaque grey color cap and opaque peach color body imprinted with “E” on cap and “73” on the body with edible black ink.

    Bottles of 15                                       NDC: 76420-630-15 (relabeled from NDC: 65862-527-47)
    Bottles of 30                                       NDC: 76420-630-30 (repackaged from NDC: 65862-527-xx)
    Bottles of 60                                       NDC: 76420-630-60 (repackaged from NDC: 65862-527-xx)
    Bottles of 90                                       NDC: 76420-630-90 (repackaged from NDC: 65862-527-xx)
    Bottles of 100                                     NDC: 76420-630-01 (relabeled from NDC: 65862-527-01)


    Venlafaxine Hydrochlorid     e Extended-Release Capsules USP, 75 mgare white to off white spherical to oval pellets filled in empty hard gelatin capsule shell (size ‘1’) of opaque peach color cap and opaque peach color body imprinted with “E” on cap and “74” on the body with edible black ink.

    Bottles of 15                                        NDC: 76420-631-15 (relabeled from NDC: 65862-528-47)
    Bottles of 30                                        NDC: 76420-631-30 (repackaged from NDC: 65862-528-xx)
    Bottles of 60                                        NDC: 76420-631-60 (repackaged from NDC: 65862-528-xx)
    Bottles of 90                                        NDC: 76420-631-90 (repackaged from NDC: 65862-528-xx)
    Bottles of 10                                        NDC: 76420-631-01 (relabeled from NDC: 65862-528-01)

    Venlafaxine Hydrochlorid     e Extended-Release Capsules USP, 150 mgare white to off white spherical to oval pellets filled in empty hard gelatin capsule shell (size ‘0’) of opaque dark orange color cap and opaque dark orange color body imprinted with “E” on cap and “89” on the body with edible black ink.

    Bottles of 15                                      NDC: 76420-632-15 (relabeled from NDC: 65862-697-47)
    Bottles of 30                                      NDC: 76420-632-30 (repackaged from NDC: 65862-697-xx)
    Bottles of 60                                      NDC: 76420-632-60 (repackaged from NDC: 65862-697-xx)
    Bottles of 90                                      NDC: 76420-632-90 (repackaged from NDC: 65862-697-xx)
    Bottles of 100                                    NDC: 76420-632-01 (relabeled from NDC: 65862-697-01)

    Store at     20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]

  • 17 PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling ( Medication Guide).

    Suicidal Thoughts and Behaviors

    Advise patients and caregivers to look for the emergence of suicidality, especially early during treatment and when the dose is adjusted up or down, and instruct them to report such symptoms to the healthcare provider [see  Boxed Warningand Warnings and Precautions (5.1)] .

    Concomitant Medication

    Instruct patients not to take venlafaxine hydrochloride extended-release capsules with an MAOI or within 14 days of stopping an MAOI [see Contraindications (4)].

    Serotonin Syndrome

    Caution patients about the risk of serotonin syndrome, particularly with the concomitant use of venlafaxine hydrochloride extended-release capsules  with other serotonergic drugs including triptans, tricyclic antidepressants, opioids, lithium, tryptophan, buspirone, amphetamines, St. John’s Wort, and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid). Instruct patients to contact their healthcare provider or report to the emergency room if they experience signs or symptoms of serotonin syndrome [seeWarnings and Precautions (5.2)andDrug Interactions (7.1)].

    Elevated Blood Pressure

    Advise patients that they should have regular monitoring of blood pressure when taking venlafaxine hydrochloride extended-release capsules [see Warnings and Precautions (5.3)] .

    Increased Risk of Bleeding

    Inform patients about the concomitant use of venlafaxine hydrochloride extended-release capsules with NSAIDs, aspirin, other antiplatelet drugs, warfarin, or other drugs that affect coagulation because the combined use has been associated with an increased risk of bleeding. Advise patients to inform their health care providers if they are taking or planning to take any prescription or over-the-counter medications that increase the risk of bleeding [see Warnings and Precautions (5.4)] .

    Activation of Mania/Hypomania

    Advise patients, their families and caregivers to observe for signs of activation of mania/hypomania and instruct them to report such symptoms to the healthcare provider [see Warnings and Precautions (5.6)] .

    Cardiovascular/Cerebrovascular Disease

    Caution is advised in administering venlafaxine hydrochloride extended-release capsules to patients with cardiovascular, cerebrovascular, or lipid metabolism disorders [see Adverse Reactions (6.1)] .

    Serum Cholesterol and Triglyceride Elevation

    Advise patients that elevations in total cholesterol, LDL and triglycerides may occur and that measurement of serum lipids may be considered [see Adverse Reactions (6.1)] .

    Discontinuation Syndrome

    Advise patients not to abruptly stop taking venlafaxine hydrochloride extended-release capsules without talking first with their healthcare provider. Patients should be aware that discontinuation effects may occur when stopping venlafaxine hydrochloride extended-release capsules and they should monitor for discontinuation symptoms [see Warnings and Precautions (5.7)and Adverse Reactions (6.1)] .

    Sexual Dysfunction

    Advise patients that use of venlafaxine hydrochloride extended-release capsules may cause symptoms of sexual dysfunction in both male and female patients. Inform patients that they should discuss any changes in sexual function and potential management strategies with their healthcare provider [see Warnings and Precautions (5.13)].

    Interference with Cognitive and Motor Performance

    Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain that venlafaxine hydrochloride extended-release capsules therapy does not adversely affect their ability to engage in such activities.

    Alcohol

    Advise patients to avoid alcohol while taking venlafaxine hydrochloride extended-release capsules [see Drug Interactions (7.2)] .

    Allergic Reactions

    Advise patients to notify their healthcare provider if they develop allergic phenomena such as rash, hives, swelling, or difficulty breathing [see  Contraindications (4)and Adverse Reactions (6.2)] .

    Pregnancy

    Advise patients to notify their healthcare provider if they become pregnant or intend to become pregnant during treatment with venlafaxine hydrochloride extended-release capsules. Advise patients that venlafaxine hydrochloride extended-release capsules use during mid to late pregnancy may lead to an increased risk for preeclampsia and may increase the risk for neonatal complications requiring prolonged hospitalization, respiratory support, and tube feeding. Advise patients that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to venlafaxine hydrochloride extended-release capsules during pregnancy [see Use in Specific Populations (8.1)] .

    Residual Spheroids

    Venlafaxine hydrochloride extended-release capsule contains spheroids, which release the drug slowly into the digestive tract. The insoluble portion of these spheroids is eliminated, and patients may notice spheroids passing in the stool or via colostomy. Patients should be informed that the active medication has already been absorbed by the time the patient sees the spheroids.

    Dispense with Medication Guide available at:     www.aurobindousa.com/medication-guides

    Brands listed are trademarks of their respective owners.

    Relabeled and Repackaged by:

    Enovachem PHARMACEUTICALS

    Torrance, CA 90501

  • MEDICATION GUIDE

    MEDICATION GUIDE
    Venlafaxine Hydrochloride Extended-Release Capsules, USP
    (ven'' la fax' een hye'' droe klor' ide)
    What is the most important information I should know about venlafaxine hydrochloride extended-release capsules?
    Venlafaxine hydrochloride extended-release capsules may cause serious side effects, including:
    • Increased risk of suicidal thoughts and actions. Venlafaxine hydrochloride extended-release capsules and other antidepressant medicines may increase suicidal thoughts and actions in some children, adolescents, and young adults, especially within the first few months of treatment or when the dose is changed. Venlafaxine hydrochloride extended-release capsules are not for use in children.
      • Depression or other serious mental illnesses are the most important causes of suicidal thoughts or actions.
           How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?
    • Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed.
    • Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings.
    • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms. 
         Call your healthcare provider or get emergency help right away if you or a family member have any of the following symptoms, especially if they are new, worse, or worry you: 

    • attempts to commit suicide 
    • acting aggressive, being angry, or violent
    • new or worse depression
    • panic attacks
    • new or worse irritability
    • an extreme increase in activity or talking (mania)
    • thoughts about suicide or dying
    • acting on dangerous impulses
    • new or worse anxiety
    • feeling very agitated or restless
    • trouble sleeping
    • other unusual changes in behavior or mood 
    What are venlafaxine hydrochloride extended-release capsules?

    Venlafaxine hydrochloride extended-release capsules are a prescription medicine used to treat adults with:  
    • a certain type of depression called Major Depressive Disorder (MDD)
    • Generalized Anxiety Disorder (GAD)
    • Social Anxiety Disorder (SAD)
    • Panic Disorder (PD)
    It is not known if venlafaxine hydrochloride extended-release capsules are safe and effective for use in children.
    Do not take venlafaxine hydrochloride extended-release capsules if you:
    • are allergic to venlafaxine hydrochloride, desvenlafaxine succinate, or any of the ingredients in venlafaxine hydrochloride extended-release capsules. See the end of this Medication Guide for a complete list of ingredients in venlafaxine hydrochloride extended-release capsules.
    • take a Monoamine Oxidase Inhibitor (MAOI)
    • have stopped taking an MAOI in the last 14 days
    • are being treated with the antibiotic linezolid or intravenous methylene blue  
    Ask your healthcare provider or pharmacist if you are not sure if you take an MAOI, including MAOIs such as linezolid or intravenous methylene blue.

    Do not start taking an MAOI for at least 7 days after you stop treatment with venlafaxine hydrochloride extended-release capsules.
    Before taking venlafaxine hydrochloride extended-release capsules tell your healthcare provider about all your medical conditions, including if you:
    • have, or have a family history of suicide, bipolar disorder, depression, mania or hypomania
    • have high blood pressure
    • have heart problems
    • have cerebrovascular problems or had a stroke
    • have or have had bleeding problems
    • have high pressure in the eye (glaucoma)
    • have high cholesterol or high triglycerides
    • have kidney or liver problems
    • have or had seizures or convulsions
    • have low sodium levels in your blood
    • have lung problems
    • drink alcohol
    • are pregnant or plan to become pregnant. Venlafaxine hydrochloride extended-release capsules may harm your unborn baby. Talk to your healthcare provider about the risk to you and your unborn baby if you take venlafaxine hydrochloride extended-release capsules during pregnancy.
      • Tell your healthcare provider if you become pregnant or think you are pregnant during treatment with venlafaxine hydrochloride extended-release capsules.
      • Pregnancy Exposure Registry.There is a pregnancy registry for women who are exposed to venlafaxine hydrochloride extended-release capsules during pregnancy. The purpose of the registry is to collect information about the health of you and your baby. If you become pregnant during treatment with venlafaxine hydrochloride extended-release capsules, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants. You can register by calling 1-844-405-­6185 or by visiting online at https://womensmentalhealth.org/research/pregnancyregistry/antidepressants.
    • are breastfeeding or plan to breastfeed. Venlafaxine hydrochloride passes into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby during treatment with venlafaxine hydrochloride extended-release capsules.
    Tell your healthcare provider about all the medicines you take,including prescription and over-the-counter medicines, vitamins, and herbal supplements.

    Venlafaxine hydrochloride extended-release capsules and other medicines may affect each other causing possible serious side effects. Venlafaxine hydrochloride extended-release capsules may affect the way other medicines work and other medicines may affect the way venlafaxine hydrochloride extended-release capsules work.

    Especially tell your healthcare provider if you take:
    • medicines to treat migraine headaches known as triptans
    • tricyclic antidepressants
    • lithium
    • tramadol, fentanyl, meperidine, methadone, or other opioids
    • tryptophan
    • buspirone
    • amphetamines
    • St. John’s Wort
    • phentermine
    • other medicines containing desvenlafaxine or venlafaxine
    • medicines that can affect blood clotting such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), warfarin  
    Ask your healthcare provider if you are not sure if you are taking any of these medicines. Your healthcare provider can tell you if it is safe to take venlafaxine hydrochloride extended-release capsules with your other medicines.

    Do not start or stop any other medicines during treatment with venlafaxine hydrochloride extended-release capsules without first talking to your healthcare provider. Stopping venlafaxine hydrochloride extended-release capsules suddenly may cause you to have serious side effects. See “What are the possible side effects of venlafaxine hydrochloride extended-release capsules?”

    Know the medicines you take. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.
    How should I take venlafaxine hydrochloride extended-release capsules?
    • Take venlafaxine hydrochloride extended-release capsules exactly as your healthcare provider tells you to. Do not change your dose or stop taking venlafaxine hydrochloride extended-release capsules without first talking to your healthcare provider.
    • Your healthcare provider may need to change the dose of venlafaxine hydrochloride extended-release capsules until it is the right dose for you.
    • Take venlafaxine hydrochloride extended-release capsules 1 time each day with food.
    • Venlafaxine hydrochloride extended-release capsules may be taken either in the morning or in the evening, but take it the same way each time.
    • Swallow venlafaxine hydrochloride extended-release capsules whole with fluid. Do not divide, crush, chew, or dissolve venlafaxine hydrochloride extended-release capsules.
    • If you cannot swallow venlafaxine hydrochloride extended-release capsules whole, the venlafaxine hydrochloride extended-release capsules may be opened and the entire contents sprinkled on a spoonful of applesauce.
      • Swallow the venlafaxine hydrochloride extended-release capsules and applesauce mixture right away without chewing.
      • Follow with a glass of water to make sure you have swallowed all of the venlafaxine hydrochloride extended-release pellets.
    • If you take too much venlafaxine hydrochloride, call your healthcare provider or poison control center at 1-800-222-1222 or go to the nearest hospital emergency room right away.
    What should I avoid while taking venlafaxine hydrochloride extended-release capsules?
    • Do not drive, or operate heavy machinery, or do other dangerous activities until you know how venlafaxine hydrochloride extended-release capsules affect you. Venlafaxine hydrochloride extended-release capsules can make you drowsy.
    • You should not drink alcohol during treatment with venlafaxine hydrochloride extended-release capsules. Drinking alcohol during treatment with venlafaxine hydrochloride extended-release capsules can increase your risk of having serious side effects.
    What are the possible side effects of venlafaxine hydrochloride extended-release capsules?
    Venlafaxine hydrochloride extended-release capsules may cause serious side effects, including:
    • See “What is the most important information I should know about venlafaxine hydrochloride extended-release capsules?”
    • Serotonin syndrome.Taking venlafaxine hydrochloride extended-release capsules can cause a potentiallylife-threatening problem called serotonin syndrome. The risk of developing serotonin syndrome is increased when venlafaxine hydrochloride extended-release capsules are taken with certain other medicines. See “Do not take venlafaxine hydrochloride extended-release capsules if you:”Stop taking venlafaxine hydrochloride extended-release capsules and call your healthcare provider or go to the nearest hospital emergency room right away if you have any of the following signs and symptoms of serotonin syndrome:  
      • agitation
      • confusion
      • fast heartbeat
      • dizziness
      • flushing
      • tremors, stiff muscles, or muscle twitching
      • seizures
      • seeing or hearing things that are not real (hallucinations)
      • coma
      • changes in blood pressure
      • sweating
      • high body temperature (hyperthermia)
      • loss of coordination
      • nausea, vomiting, diarrhea 
    • Increases in blood pressure.Your healthcare provider should check your blood pressure before starting treatment and regularly during treatment with venlafaxine hydrochloride extended-release capsules. If you have high blood pressure, it should be controlled before you start treatment with venlafaxine hydrochloride extended-release capsules.
    • Increased risk of bleeding.Taking venlafaxine hydrochloride extended-release capsules with aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or blood thinners may add to this risk. Tell your healthcare provider right away about any unusual bleeding or bruising.
    • Eye problems (angle-closure glaucoma).Venlafaxine hydrochloride extended-release capsules may cause a certain type of eye problem called angle-closure glaucoma. You may want to undergo an eye examination to see if you are at risk and receive preventative treatment if you are. Call your healthcare provider if you have eye pain, changes in your vision, or swelling or redness in or around the eye.
    • Manic episodes.Manic episodes may happen in people with bipolar disorder who take venlafaxine hydrochloride extended-release capsules. Symptoms may include:
      • greatly increased energy
      • racing thoughts
      • unusually grand ideas
      • talking more or faster than usual
      • severe trouble sleeping
      • reckless behavior
      • excessive happiness or irritability 
    • Discontinuation syndrome.Suddenly stopping venlafaxine hydrochloride extended-release capsules may cause you to have serious side effects. Your healthcare provider may want to decrease your dose slowly. Symptoms may include:  
      • dizziness
      • irritability and agitation
      • anxiety
      • sweating
      • seizures
      • ringing in your ears (tinnitus)
      • nausea
      • problems sleeping
      • tiredness
      • confusion
      • electric shock sensation (paresthesia)
      • headache
      • diarrhea
      • abnormal dreams
      • changes in your mood
      • hypomania 
    • Seizures (convulsions).
    • Low sodium levels in your blood (hyponatremia).Low sodium levels can happen during treatment with venlafaxine hydrochloride extended-release capsules. Low sodium levels in your blood may be serious and may cause death. Elderly people may be at greater risk for this. Signs and symptoms of low sodium levels in your blood may include:
      • headache
      • difficulty concentrating
      • memory changes
      • confusion
      • weakness and unsteadiness on your feet which can lead to falls  
    In severe or more sudden cases, signs and symptoms include: 
    • hallucinations (seeing or hearing things that are not real)
    • fainting
    • seizures
    • coma
    • respiratory arrest  
    • Lung problems.Some people who have taken the medicine venlafaxine, which is the same kind of medicine as the medicine in venlafaxine hydrochloride extended-release capsules, have had lung problems. Symptoms of lung problems include difficulty breathing, cough, or chest discomfort. Tell your healthcare provider right away if you have any of these symptoms.
    • Sexual problems (dysfunction).Taking selective serotonin reuptake inhibitors (SNRIs), including venlafaxine hydrochloride extended-release capsules, may cause sexual problems.  
    Symptoms in males may include:
    • delayed ejaculation or inability to have an ejaculation
    • decreased sex drive
    • problems getting or keeping an erection  
    Symptoms in females may include:
    • decreased sex drive
    • delayed orgasm or inability to have an orgasm  
    Talk to your healthcare provider if you develop any changes in your sexual function or if you have any questions or concerns about sexual problems during treatment with venlafaxine hydrochloride extended-release capsules. There may be treatments your healthcare provider can suggest.

    Your healthcare provider may tell you to stop taking venlafaxine hydrochloride extended-release capsules if you develop serious side effects during treatment with venlafaxine hydrochloride extended-release capsules.
    The most common side effects of venlafaxine hydrochloride extended-release capsules include:
    • nausea
    • dry mouth
    • male and female sexual problems
    • loss of appetite (anorexia)
    • sleepiness
    • sweating
    • constipation 
    These are not all the possible side effects of venlafaxine hydrochloride extended-release capsules.
    Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    How should I store venlafaxine hydrochloride extended-release capsules?
    • Store venlafaxine hydrochloride extended-release capsules at room temperature between 20° to 25°C (68° to 77°F).
    • Keep venlafaxine hydrochloride extended-release capsules in a dry place.
    Keep venlafaxine hydrochloride extended-release capsules and all medicines out of the reach of children.
    General information about the safe and effective use of venlafaxine hydrochloride extended-release capsules.
    Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use venlafaxine hydrochloride extended-release capsules for a condition for which it was not prescribed. Do not give venlafaxine hydrochloride extended-release capsules to other people, even if they have the same symptoms that you have. They may harm them. You can ask your healthcare provider or pharmacist for information about venlafaxine hydrochloride extended-release capsules that is written for healthcare professionals.
    What are the ingredients in venlafaxine hydrochloride extended-release capsules?
    Active ingredient:Venlafaxine hydrochloride

    Inactive ingredients:Ethyl cellulose, hypromellose, sugar spheres, and talc. The empty hard gelatin capsule shells contain iron oxide red, gelatin, titanium dioxide, and sodium lauryl sulphate. In addition, the 37.5 mg empty hard gelatin capsule shells contain iron oxide black. The capsules are printed with edible ink containing black iron oxide and shellac.

    Relabeled and Repackaged by:

    Enovachem PHARMACEUTICALS

    Torrance, CA 90501


    For more information about venlafaxine hydrochloride extended-release capsules call 1-866-850-2876.

    This Medication was approved by the U.S. Food and Drug Administration.

    Revised: 09/2023

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 37.5 mg


    PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 37.5 mg

  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL -75 mg


    PACKAGE LABEL-PRINCIPAL DISPLAY PANEL -75 mg


  • PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 150 mg



    PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 150 mg

  • INGREDIENTS AND APPEARANCE
    VENLAFAXINE HYDROCHLORIDE  
    venlafaxine hydrochloride capsule, extended release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 76420-631(NDC:65862-528)
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG) VENLAFAXINE75 mg
    Inactive Ingredients
    Ingredient NameStrength
    ETHYLCELLULOSE (20 MPA.S) (UNII: BJG0S321QY)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    SUCROSE (UNII: C151H8M554)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    TALC (UNII: 7SEV7J4R1U)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    GELATIN, UNSPECIFIED (UNII: 2G86QN327L)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    SHELLAC (UNII: 46N107B71O)  
    Product Characteristics
    Colororange (Opaque Peach) Scoreno score
    ShapeCAPSULESize19mm
    FlavorImprint Code E;74
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 76420-631-1515 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    2NDC: 76420-631-3030 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    3NDC: 76420-631-6060 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    4NDC: 76420-631-9090 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    5NDC: 76420-631-01100 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20083406/01/2011
    VENLAFAXINE HYDROCHLORIDE  
    venlafaxine hydrochloride capsule, extended release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 76420-630(NDC:65862-527)
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG) VENLAFAXINE37.5 mg
    Inactive Ingredients
    Ingredient NameStrength
    ETHYLCELLULOSE (20 MPA.S) (UNII: BJG0S321QY)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    SUCROSE (UNII: C151H8M554)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    TALC (UNII: 7SEV7J4R1U)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    GELATIN, UNSPECIFIED (UNII: 2G86QN327L)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    SHELLAC (UNII: 46N107B71O)  
    Product Characteristics
    Colororange (Opaque Peach) , gray (Opaque Grey) Scoreno score
    ShapeCAPSULESize16mm
    FlavorImprint Code E;73
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 76420-630-1515 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    2NDC: 76420-630-3030 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    3NDC: 76420-630-6060 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    4NDC: 76420-630-9090 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    5NDC: 76420-630-01100 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20083406/01/2011
    VENLAFAXINE HYDROCHLORIDE  
    venlafaxine hydrochloride capsule, extended release
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 76420-632(NDC:65862-697)
    Route of AdministrationORAL
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    VENLAFAXINE HYDROCHLORIDE (UNII: 7D7RX5A8MO) (VENLAFAXINE - UNII:GRZ5RCB1QG) VENLAFAXINE150 mg
    Inactive Ingredients
    Ingredient NameStrength
    ETHYLCELLULOSE (20 MPA.S) (UNII: BJG0S321QY)  
    HYPROMELLOSE 2910 (5 MPA.S) (UNII: R75537T0T4)  
    SUCROSE (UNII: C151H8M554)  
    STARCH, CORN (UNII: O8232NY3SJ)  
    TALC (UNII: 7SEV7J4R1U)  
    FERRIC OXIDE RED (UNII: 1K09F3G675)  
    GELATIN, UNSPECIFIED (UNII: 2G86QN327L)  
    TITANIUM DIOXIDE (UNII: 15FIX9V2JP)  
    SODIUM LAURYL SULFATE (UNII: 368GB5141J)  
    FERROSOFERRIC OXIDE (UNII: XM0M87F357)  
    SHELLAC (UNII: 46N107B71O)  
    Product Characteristics
    Colororange (Opaque Dark Orange) Scoreno score
    ShapeCAPSULESize21mm
    FlavorImprint Code E;89
    Contains    
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 76420-632-1515 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    2NDC: 76420-632-3030 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    3NDC: 76420-632-6060 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    4NDC: 76420-632-9090 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    5NDC: 76420-632-01100 in 1 BOTTLE; Type 0: Not a Combination Product10/18/2023
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA20083411/23/2011
    Labeler - Asclemed USA, Inc. (059888437)
    Establishment
    NameAddressID/FEIBusiness Operations
    ASCLEMED USA INC. DBA ENOVACHEM059888437relabel(76420-630, 76420-631, 76420-632) , repack(76420-630, 76420-631, 76420-632)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.